viru
infect
host
cell
sens
innat
pattern
recognit
receptor
prr
induc
product
type
interferon
ifn
inflammatori
cytokin
cytokin
orchestr
elimin
virus
occasion
detriment
host
outcom
pathogenesi
viral
infect
larg
determin
specif
interact
virus
host
cell
therefor
compound
either
inhibit
viral
infect
modul
virusinduc
cytokin
respons
consid
candid
manag
viru
infect
aim
studi
identifi
compound
categori
use
singl
cellbas
assay
screen
platform
cellbas
report
assay
express
firefli
luciferas
control
human
ifnb
promot
demonstr
infect
report
cell
line
panel
rna
virus
activ
report
gene
express
correl
quantit
level
viru
replic
progeni
viru
product
could
inhibit
dosedepend
manner
known
antivir
compound
inhibitor
prr
signal
transduct
pathway
use
dengu
viru
exampl
pilot
screen
small
molecul
librari
consist
compound
prove
concept
ifnb
promot
report
assay
serv
conveni
high
throughput
screen
platform
simultan
discoveri
antivir
innat
immun
respons
modul
compound
repres
antivir
compound
pilot
screen
urea
demonstr
specif
inhibit
sever
virus
belong
famili
flavivirida
viral
infecti
diseas
remain
major
public
health
challeng
worldwid
signific
progress
made
last
two
decad
develop
clinic
applic
antivir
drug
sever
medic
import
virus
includ
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
fung
et
al
jilek
et
al
yang
et
al
antivir
mani
rna
virus
caus
hemorrhag
fever
respiratori
tract
diseas
either
limit
efficaci
yet
avail
chang
et
al
fulfil
unmet
medic
need
intend
develop
conveni
assay
highthroughput
discoveri
compound
either
inhibit
replic
virus
allevi
pathogenesi
usual
result
uncontrol
cytokin
respons
viral
infect
sometim
lifethreaten
achiev
goal
design
implement
cellbas
high
throughput
assay
appli
mani
type
virus
suitabl
simultan
identif
compound
either
inhibit
viral
replic
modul
virusinduc
cytokin
respons
principl
assay
base
innat
immun
recognit
viru
infect
host
innat
pattern
recognit
receptor
prr
includ
tolllik
receptor
tlr
rigilik
receptor
rlr
nodlik
receptor
ctype
lectin
mani
other
takeuchi
akira
prr
molecular
pattern
virus
viral
nucleic
acid
oligom
envelop
protein
nucleocapsid
induc
cellular
respons
lead
product
type
interferon
ifn
proinflammatori
cytokin
chemokin
akira
activ
ifn
respons
common
featur
mani
differ
virus
establish
cellbas
report
system
express
firefli
luciferas
gene
control
human
ifnb
promot
quantit
monitor
viru
activ
host
innat
immun
respons
specif
stabl
cell
line
use
studi
intrins
rlr
pathway
reconstitut
pathway
primari
prr
mani
rna
virus
loo
gale
negishi
et
al
therefor
respons
infect
virus
inde
demonstr
infect
cell
line
rna
virus
five
differ
famili
effici
activ
ifnb
promot
driven
luciferas
product
interestingli
level
report
gene
express
upon
viru
infect
quantit
correl
level
viru
replic
progeni
virion
product
thu
specul
subsequ
demonstr
level
luciferas
express
viral
infect
cell
serv
simpl
quantit
readout
viral
replic
activ
high
throughput
manner
anticip
pilot
screen
compound
convincingli
demonstr
ifnb
promot
report
assay
use
broadli
applic
platform
discoveri
compound
antivir
activ
mani
differ
virus
well
compound
inhibit
virusinduc
cytokin
respons
repres
antivir
compound
pilot
screen
urea
character
detail
demonstr
specif
inhibit
sever
virus
belong
famili
flavivirida
cell
maintain
dulbecco
modifi
minim
essenti
medium
dmem
invitrogen
supplement
fetal
bovin
serum
blight
et
al
invivogen
deriv
stabl
report
cell
line
express
firefli
luciferas
control
human
ifnb
promot
establish
cultur
describ
previous
dengu
viru
denv
serotyp
new
guinea
c
yellow
fever
viru
yfv
strain
encephalomyocard
viru
emcv
tacarib
viru
tcrv
strain
hcv
genotyp
strain
describ
previous
chang
et
al
chang
et
al
jiang
et
al
qu
et
al
zhou
et
al
sendai
viru
senv
strain
purchas
atcc
hcv
subgenom
repliconcontain
cell
line
describ
previous
guo
et
al
imino
sugar
compound
known
antidenv
activ
chang
et
al
du
et
al
synthes
hous
puriti
compound
benzothiazolylphenyl
urea
bpu
purchas
chemdiv
pbl
inc
cell
seed
black
wallclear
bottom
plate
corn
inc
firefli
luciferas
activ
differ
experiment
condit
measur
ad
equal
volum
steadyglo
reagent
promega
follow
luminometri
topcount
perkin
elmer
librari
contain
small
molecular
compound
chemdiv
dougherti
et
al
screen
cell
seed
plate
well
cultur
overnight
plate
column
well
mockinfect
serv
uninfect
control
column
well
infect
denv
multipl
infect
moi
four
well
treat
dmso
serv
mock
treat
control
effect
readout
compar
without
dmso
data
shown
remain
four
well
treat
lm
serv
posit
drug
treatment
control
remain
well
column
infect
denv
moi
treat
librari
compound
lm
dmso
treatment
initi
immedi
follow
infect
luciferas
activ
determin
h
post
infect
although
assay
liquidhandl
compat
due
use
infecti
viru
ht
perform
manual
use
multichannel
pipett
typic
fifti
plate
contain
librari
compound
test
singl
experi
addit
control
plate
half
plate
infect
denv
moi
half
plate
uninfect
includ
experi
z
factor
plate
calcul
use
data
infect
control
well
uninfect
control
well
rang
z
factor
experi
calcul
base
paramet
obtain
control
plate
rang
compound
reduc
luciferas
activ
mock
treat
control
andor
demonstr
superior
potenc
comparison
posit
control
drug
score
primari
hit
primari
hit
subject
evalu
dosedepend
effect
luciferas
activ
denvinfect
report
cell
well
cytotox
uninfect
cell
mtt
assay
promega
compound
dosedepend
reduc
denvinduc
luciferas
express
ec
valu
less
lm
reduc
cell
viabil
less
lm
consid
confirm
hit
confirm
hit
evalu
incel
western
assay
identifi
compound
inhibit
denv
infect
human
hepatoma
cell
line
compound
antivir
activ
denv
test
activ
emcv
tcrv
induc
ifnb
report
express
ifnbluc
cell
determin
antivir
spectrum
confirm
hit
inhibit
viru
infect
consid
candid
innat
immun
pathway
inhibitor
antivir
activ
denv
yfv
evalu
incel
western
assay
essenti
describ
previous
jiang
et
al
yu
et
al
briefli
cell
plate
infect
denv
yfv
moi
mocktreat
dmso
treat
serial
dilut
compound
h
cell
fix
incub
mous
monoclon
antibodi
millipor
flaviviru
envelop
e
protein
follow
incub
antimous
irdy
secondari
antibodi
togeth
two
reagent
cell
stain
biostatu
licor
denv
yfv
e
protein
visual
licor
odyssey
channel
green
cell
viabil
determin
channel
red
fluoresc
signal
intens
quantifi
licor
odyssey
determin
denv
yield
cell
cell
infect
denv
moi
h
remov
inoculum
cell
treat
indic
incub
viru
titer
cultur
media
determin
use
monolay
vero
cell
infect
dilut
media
h
follow
overlay
media
contain
methylcellulos
incub
day
viral
foci
detect
immunostain
antibodi
millipor
count
plaqu
crystal
violet
stain
chang
et
al
determin
cell
viabil
mtt
assay
sigma
perform
describ
previous
chang
et
al
cell
set
incub
variou
concentr
compound
condit
ident
use
antivir
luciferas
assay
except
cell
infect
total
cellular
rna
extract
cell
day
post
infect
hcv
moi
use
trizol
invitrogen
quantit
rtpcr
qrtpcr
reaction
perform
lightcycl
roch
use
probe
primer
describ
previous
hcv
infect
cell
fix
pb
contain
paraformaldehyd
follow
incub
triton
min
cell
block
incub
monoclon
antibodi
hcv
protein
kindli
provid
dr
chen
liu
univers
florida
bound
primari
antibodi
visual
alexa
fluor
goat
antimous
igg
invitrogen
zhu
et
al
detect
hcv
cell
lyse
laemmli
buffer
protein
lysat
resolv
electrophoresi
trisglycin
gel
transfer
onto
nitrocellulos
membran
invitrogen
membran
block
probe
antibodi
hcv
gift
dr
chen
liu
univers
florida
bactin
sigma
follow
incub
irdy
secondari
antibodi
imag
licor
odyssey
system
licor
biotechnolog
total
cellular
rna
extract
cell
trizol
invitrogen
six
microgram
total
rna
load
agaros
gel
contain
formaldehyd
transfer
onto
nylon
membran
membran
hybrid
riboprob
specif
plusstrand
hcv
replicon
rna
describ
previous
chang
et
al
hcv
pseudotyp
particl
hcvpp
assay
plasmid
e
firefli
luciferas
gene
insert
nef
gene
two
frameshift
render
envand
vpr
obtain
nih
aid
research
refer
reagent
program
connor
et
al
et
al
plasmid
express
hcv
strain
envelop
protein
construct
larg
previous
report
tong
et
al
pcmvvsvg
plasmid
express
vesicular
stomat
viru
vsv
g
envelop
protein
obtain
addgen
hcv
envelop
proteinand
vsv
g
proteinpseudotyp
lentivir
particl
design
hcvpp
vsvpp
respect
packag
cell
briefli
cell
seed
mm
plate
night
cell
cotransfect
lg
etogeth
lg
pcmvvsvg
use
calcium
phosphat
precipit
procedur
twentyfour
hour
post
transfect
cell
replenish
complet
dmem
cultur
media
harvest
h
hcvpp
h
vsvpp
post
transfect
filter
lm
pore
size
pe
filter
millipor
determin
effect
hit
compound
hcv
entri
cell
seed
cellswel
plate
night
cell
infect
pseudotyp
particl
absenc
presenc
test
compound
h
inoculum
compound
remov
replac
complet
medium
three
day
post
infect
luciferas
activ
determin
describ
z
factor
z
calcul
use
follow
equat
l
p
l
n
repres
mean
valu
uninfect
control
well
infect
control
well
p
n
standard
deviat
zhang
et
al
coeffici
variat
cv
calcul
use
follow
equat
cv
dl
correl
replic
plate
assess
pair
wise
pearson
correl
analysi
cytoplasm
rlr
endosom
primari
prr
sever
rna
virus
loo
gale
negishi
et
al
order
quantit
measur
rlrmediat
innat
antivir
immun
respons
cell
line
stabli
express
firefli
luciferas
report
gene
control
human
ifnb
promot
li
et
al
design
establish
cell
line
intact
intrins
rlr
pathway
reconstitut
pathway
yoneyama
et
al
report
gene
respond
infect
virus
abl
activ
one
pathway
inde
shown
fig
infect
cell
line
denv
yfv
tcrv
emcv
senv
induc
luciferas
express
inoculum
size
moi
hemagglutin
unit
hau
depend
manner
demonstr
ifnb
promot
report
signal
proport
size
viral
inoculum
fig
next
determin
relationship
level
viral
replic
report
gene
express
use
denv
exampl
cell
infect
denv
moi
luciferas
activ
viru
titer
determin
h
post
infect
shown
fig
b
uv
inactivateddenv
induc
detect
ifnb
promot
activ
level
luciferas
express
live
denv
infect
cell
quantit
correl
viru
yield
result
indic
viru
induct
ifnb
gene
express
reli
activ
viral
replic
also
report
level
viral
replic
suffici
dynam
rang
therefor
could
potenti
use
conveni
antivir
assay
measur
antivir
activ
compound
confirm
notion
cell
infect
denv
treat
serial
dilut
imino
sugar
compound
inhibit
virion
particl
assembl
secret
denv
inhibit
glycosyl
matur
viral
envelop
protein
e
protein
chang
et
al
b
control
cell
infect
denv
similarli
treat
denv
e
protein
determin
incel
western
assay
h
post
infect
shown
fig
b
inhibit
luciferas
express
cell
viral
e
protein
cell
dose
depend
manner
result
ec
valu
lm
respect
result
thu
valid
ifnb
report
assay
could
use
conveni
antivir
assay
denv
potenti
virus
abl
activ
ifn
respons
cell
line
result
present
indic
ifnb
promot
report
assay
quantit
report
viral
infect
henc
could
potenti
develop
cellbas
high
throughput
screen
assay
identif
antivir
compound
compound
inhibit
virusinduc
cytokin
respons
optim
perform
assay
high
throughput
format
initi
set
determin
key
paramet
might
affect
perform
assay
low
moi
infect
prefer
allow
multipl
round
viral
infect
experiment
period
thu
permit
identif
antivir
compound
interf
step
viral
replic
cycl
shown
tabl
condit
denv
infect
moi
cell
densiti
cellswel
highest
signaltobackground
ratio
sb
z
valu
cv
achiev
infect
moi
result
steadi
increas
luciferas
sb
ratio
develop
cytopath
effect
fig
data
shown
ht
experi
chosen
carri
condit
h
evalu
perform
ht
assay
six
hypothet
replic
plate
seed
process
follow
plate
well
left
uninfect
well
infect
denv
mock
treat
rest
well
infect
denv
treat
indic
concentr
posit
control
compound
h
shown
tabl
fig
z
factor
rang
sb
ratio
rang
obtain
test
plate
dosedepend
inhibit
luciferas
activ
ec
valu
rang
lm
result
thu
suggest
assay
select
experiment
condit
high
signaltobackground
ratio
low
variat
furthermor
pearson
coeffici
determin
rang
among
replic
plate
fig
suggest
high
reproduc
ht
assay
screen
librari
compound
carri
establish
ht
experiment
condit
describ
raw
luciferas
valu
normal
percentag
infectedmock
treat
control
within
assay
plate
illustr
fig
compound
reduc
denv
activ
luciferas
express
greater
lm
concentr
andor
demonstr
potent
inhibitori
effect
control
compound
nomin
primari
hit
primari
hit
compound
subsequ
test
serial
dilut
rang
lm
evalu
effect
denvinduc
luciferas
activ
well
cytotox
report
cell
illustr
fig
total
compound
confirm
select
inhibit
denv
induc
luciferas
express
dosedepend
manner
confirm
hit
next
evalu
test
antivir
activ
denv
incel
western
assay
yu
et
al
cell
experi
categor
confirm
hit
two
group
group
compound
select
inhibit
product
denv
e
protein
greater
lm
thu
antivir
remain
compound
appar
affect
denv
e
protein
product
cell
dosedepend
reduc
viru
activ
ifnb
promot
activ
report
cell
suggest
like
inhibitor
viruselicit
innat
immun
respons
pathway
character
innat
immun
pathway
inhibitor
report
elsewher
antivir
compound
test
effect
ifnb
promot
activ
induc
repres
posit
strand
rna
viru
emcv
neg
strand
rna
viru
tcrv
determin
antivir
spectrum
among
antivir
compound
compound
also
activ
inhibit
emcv
tcrv
induc
ifnb
promot
activ
thu
potenti
broadspectrum
antivir
sinc
particularli
interest
discov
virusspecif
antivir
one
three
antivir
compound
inhibit
denv
emcv
tcrv
urea
benzothiazolylphenyl
urea
compound
bpu
fig
chosen
highlight
hit
evalu
studi
ec
valu
bpu
denv
determin
ifnb
report
assay
incel
western
assay
lm
lm
respect
fig
moreov
demonstr
bpu
inhibit
infect
denv
fig
judg
reduct
viru
yield
anoth
flaviviru
yfv
fig
judg
reduct
viru
e
protein
also
effici
inhibit
hcv
infect
cell
demonstr
signific
suppress
hcv
rna
replic
quantit
rtpcr
assay
fig
contrari
consist
result
obtain
ifnb
report
assay
fig
bpu
appar
inhibit
replic
tcrv
emcv
determin
viru
yield
concentr
cell
seed
plate
indic
densiti
half
plate
infect
denv
anoth
half
plate
uninfect
firefli
luciferas
activ
measur
h
post
infect
sb
signal
background
refer
ratio
luciferas
activ
infect
well
uninfect
well
cv
percentag
coeffici
variat
infect
well
z
z
factor
statist
analysi
use
paramet
obtain
infect
uninfect
well
z
z
factor
statist
analysi
use
paramet
obtain
infect
control
well
uninfect
well
reduct
assay
data
shown
henc
bpu
appear
specif
inhibitor
virus
famili
flavivirida
order
elucid
antivir
mechan
took
advantag
avail
tool
hcv
research
laboratori
map
viral
replic
step
target
bpu
shown
fig
bpu
potent
inhibit
hcv
replic
treatment
start
immedi
infect
low
moi
fig
c
compound
appar
affect
hcv
replic
treatment
initi
viru
spread
infect
cell
cultur
day
post
infect
fig
howev
expect
ifna
effici
inhibit
hcv
replic
condit
furthermor
bpu
inhibit
replic
hcv
subgenom
replicon
cell
fig
result
thu
impli
bpu
like
inhibit
earli
late
event
hcv
replic
entri
uncoat
virion
particl
assembl
secret
viral
protein
biosynthesisprocess
rna
replic
distinguish
two
possibl
demonstr
bpu
select
inhibit
infect
hcv
envelop
protein
lentivir
particl
hcvpp
vsv
g
proteinpseudotyp
lentivir
particl
vsvpp
henc
result
indic
bpu
like
inhibit
hcv
entri
host
cell
although
ifnb
report
assay
wide
use
studi
viru
induct
innat
immun
respons
report
herein
simpl
assay
also
use
screen
identif
compound
antivir
innat
immun
responsemodul
activ
high
throughput
manner
result
demonstr
highthroughput
screen
platform
follow
uniqu
featur
first
report
assay
sensit
robust
allow
screen
perform
low
moi
infect
fig
tabl
support
multipl
round
viral
infect
thu
allow
identif
compound
inhibit
step
viral
replic
cycl
contrari
mani
commonli
use
cellbas
antivir
assay
base
viru
induc
cytopath
effect
cpe
frequent
requir
high
moi
infect
may
preclud
identif
compound
target
late
event
viral
replic
cycl
addit
although
current
studi
screen
perform
plate
assay
easili
miniatur
format
adapt
use
liquid
handl
second
addit
identifi
compound
antivir
activ
ifnb
report
assay
also
use
simultan
identif
compound
inhibit
viruselicit
proinflammatori
cytokin
respons
activ
ifnb
gene
express
reli
coordin
activ
nfjb
mapk
pathway
later
two
pathway
also
requir
induc
inflammatori
cytokin
therefor
monitor
ifnb
gene
activ
viral
infect
cover
import
innat
immun
signal
pathway
although
focu
current
studi
demonstr
viru
activ
ifnb
promot
activ
dosedepend
inhibit
multipl
known
inhibitor
pathway
screen
inde
identifi
multipl
compound
properti
fig
compound
inhibit
viral
induct
cytokin
respons
could
candid
develop
drug
allevi
viral
pathogenesi
relat
cytokin
storm
encephalomening
west
nile
viru
infect
wang
et
al
hemorrhag
fever
infect
denv
ebola
viru
mani
virus
paessler
walker
pang
et
al
wauquier
et
al
well
sever
pneumonia
influenza
viru
sarscoronaviru
infect
cheng
et
al
oslund
baumgarth
theron
et
al
altern
compound
could
also
serv
chemic
genet
probe
studi
virushost
interact
unlik
sirnamedi
knockdown
genomewid
gene
discoveri
technolog
chemic
genet
approach
like
identifi
host
function
potenti
drugabl
de
chassey
et
al
panda
cherri
awar
possibl
certain
compound
identifi
antivir
activ
might
indirectli
inhibit
viral
replic
either
enhanc
viruselicit
ifn
respons
attenu
viral
suppress
ifn
respons
howev
cell
use
antivir
assay
secondari
screen
defici
rigi
pathway
unlik
antivir
compound
identifi
studi
inhibit
viral
replic
via
mechan
third
well
known
mani
speci
virus
influenza
viru
rift
valley
fever
viru
evolv
abil
inhibit
prrmediat
cytokin
respons
essenti
establish
viral
infect
vivo
critic
viral
pathogenesi
habjan
et
al
mibayashi
et
al
rajsbaum
et
al
siu
et
al
thu
ifnb
promot
report
assay
might
also
use
screen
compound
restor
innat
immun
respons
induc
virus
exampl
novel
small
molecul
inhibitor
influenza
virus
discov
screen
compound
restor
ifn
respons
influenza
viru
infect
mdck
cellbas
ifnb
promot
report
assay
ortigoza
et
al
forth
assay
resourc
effici
activ
ifn
respons
common
properti
mani
differ
virus
assay
serv
broadli
applic
ht
platform
viru
infect
cell
along
line
robust
report
assay
also
make
feasibl
parallel
screen
multipl
virus
fact
multiplex
viral
screen
reveal
virusspecif
broadspectrum
antivir
compound
well
compound
disrupt
virusspecif
common
innat
immun
respons
pathway
inform
obtain
multiplex
viral
screen
help
priorit
activ
compound
develop
therapeut
andor
molecular
probe
instanc
compound
hit
common
choke
point
host
function
requir
replic
mani
differ
virus
potenti
serv
candid
develop
broadspectrum
antivir
drug
experiment
probe
reveal
commonli
requir
host
function
viral
replic
induct
host
antivir
respons
malauer
et
al
final
character
repres
antivir
hit
pilot
ht
clearli
demonstr
feasibl
report
assay
discoveri
antivir
compound
bpu
antivir
compound
inhibit
infect
virus
least
two
genera
flavivirida
famili
emcv
tcrv
repres
posit
negativestrand
rna
virus
respect
mechanist
analysi
demonstr
compound
inhibit
entri
hcv
possibl
flavivirus
target
common
entri
factor
share
virus
chemic
bpu
nbenzothiazolyl
n
phenyl
urea
core
structur
two
alkoxi
substitut
fig
sever
analog
core
structur
found
antivir
activ
hiv
dcruz
et
al
paget
et
al
inhibit
type
iii
secret
system
pathogen
bacteria
pct
int
appl
well
inhibit
ubiquitin
ligas
pct
int
appl
wo
howev
biolog
activ
compound
uniqu
alkoxi
substitut
bpu
report
although
bpu
highli
potent
antivir
compound
structur
tractabl
chemic
modif
structureact
relationship
studi
futur
develop
potenti
antivir
therapeut
